Robert van Winkle, MD
Allergy · Greensboro, NCNPI 1336129410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 27.1% of the total.
Across 267 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$655
- Novartis$596
- GSK$433
- Kaleo, Inc.$403
- Optinose US, Inc.$393
- plus $1K from 21 others
What the payments were for
- Food & beverage$5,078100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $1,378 |
| Regeneron Healthcare Solutions, Inc. | 28 | $655 |
| Novartis | 32 | $596 |
| GSK | 26 | $433 |
| Kaleo, Inc. | 28 | $403 |
| Optinose US, Inc. | 24 | $393 |
| Sanofi | 15 | $349 |
| Amgen | 7 | $137 |
| Genentech USA, Inc. | 7 | $132 |
| Pfizer | 5 | $81 |
| Greer Laboratories, Inc. | 2 | $53 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $49 |
| Incyte Corporation | 2 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $48 |
| Organon | 2 | $43 |
| LEO Pharma Inc. | 2 | $40 |
| AbbVie | 2 | $36 |
| USWM, LLC | 2 | $32 |
| Alk-abello, Inc | 2 | $29 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$244
How this compares
Too few allergy providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 61 | $30,492 |
| SymbicortBudesonide/Formoterol Fumarate | 96 | $26,490 |
| Epinephrine | 166 | $25,247 |
| Arnuity ElliptaFluticasone Furoate | 35 | $9,675 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 50 | $9,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,075 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,544 |
| Azelastine Hcl | 137 | $3,852 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $3,456 |
| Ipratropium Bromide | 83 | $3,023 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,847 |
| Levocetirizine Dihydrochloride | 301 | $2,505 |
| Fluticasone Propionate HfaFluticasone Propionate | 17 | $2,403 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,091 |
| Fluticasone Propionate | 131 | $1,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta | $433 | $48,242107 claims |
| AstraZenecaSymbicort | $1,378 | $26,49096 claims |
| Hikma Pharmaceuticals USAEpinephrine | $29 | $25,247166 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $11 | $3,45616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other allergy in Greensboro
- Yoon KimGreensboro$14K
- Meg WhelanGreensboro$4K
- Ranjan SharmaGreensboro$2K
- Katherine OberhelmanGreensboro$365
- Eveline WuChapel Hill$136K
- Charles HumphriesCharlotte$4K
- Thomas OfferleCharlotte$781
- Hunter SmithChapel Hill$242
- Elizabeth IsbisterHarbinger$15
- Mildred KwanChapel Hill$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.